{"DataElement":{"publicId":"2500910","version":"1","preferredName":"Eligibility Inclusion Criteria 03058_01 Text Name","preferredDefinition":"Text eligibility criteria (inclusion only) that are used to evaluate candidates for enrollment into Lombardi Cancer Center trial #03058, amendment 1.","longName":"ELIG_INC_03058_01_NM","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"2500908","version":"1","preferredName":"Inclusion Eligibility Criteria Text","preferredDefinition":"Text Criteria (inclusion only) that are used to evaluate candidates for enrollment into a clinical trial.","longName":"INC_ELIG_CRIT_TXT","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2500906","version":"1","preferredName":"Inclusion Clinical Trial Eligibility Criteria","preferredDefinition":"The addition of somebody or something to, or the presence of somebody or something in, a group or mixture, particularly, a passive, usually temporary, product of cell activity within the cytoplasm or nucleus.:Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"C25532:C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inclusion Criteria","conceptCode":"C25532","definition":"Medical and/or social characteristics which are necessary for a subject to be allowed to participate in a clinical study, as outlined in the study protocol. Meeting inclusion criteria is not a sufficient condition for entry or recruitment of a subject into the study. Characteristics limiting the eligibility of a subject for the clinical study must be considered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"19E0A534-63C2-44D7-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"ONEDATA","dateModified":"2006-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2228365","version":"1","preferredName":"Text","preferredDefinition":"The words of something written.","longName":"C25704","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Text","conceptCode":"C25704","definition":"The words of something written.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F6DEAE35-C96D-734E-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-11","endDate":null,"createdBy":"UMLLOADER_COMMON","dateCreated":"2005-05-11","modifiedBy":"DWARZEL","dateModified":"2023-04-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"19E0A534-63D0-44D7-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2497513","version":"1","preferredName":"Eligibility Inclusion Criteria Question Text Name","preferredDefinition":"Text terms to capture the contents of eligibility Inclusion criteria questions for Lombardi Cancer Center, IRB #03058, amendment 1, clinical trial.","longName":"ELIG_INC_03058_01_NM","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"200","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"1. Does patient with pathologically have confirmed solid tumors for whom no standard therapies exist in Phase I?","valueDescription":"1. Does patient with pathologically have confirmed solid tumors for whom no standard therapies exist in Phase I?","ValueMeaning":{"publicId":"2580290","version":"1","preferredName":"1. Does patient with pathologically have confirmed solid tumors for whom no standard therapies exist in Phase I?","longName":"2580290","preferredDefinition":"1. Does patient with pathologically have confirmed solid tumors for whom no standard therapies exist in Phase I?","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-06AF-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-20","modifiedBy":"REEVESD","dateModified":"2006-07-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"19089E42-E223-2EAD-E044-0003BA3F9857","beginDate":"2006-07-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-20","modifiedBy":"REEVESD","dateModified":"2006-07-20","deletedIndicator":"No"},{"value":"2. Does patient have histologically or cytologically documented non-small cell carcinoma of the lung in Phase II?","valueDescription":"2. Does patient have histologically or cytologically documented non-small cell carcinoma of the lung in Phase II?","ValueMeaning":{"publicId":"2580291","version":"1","preferredName":"2. Does patient have histologically or cytologically documented non-small cell carcinoma of the lung in Phase II?","longName":"2580291","preferredDefinition":"2. Does patient have histologically or cytologically documented non-small cell carcinoma of the lung in Phase II?","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-06B0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-20","modifiedBy":"REEVESD","dateModified":"2006-07-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"19089E42-E22F-2EAD-E044-0003BA3F9857","beginDate":"2006-07-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-20","modifiedBy":"REEVESD","dateModified":"2006-07-20","deletedIndicator":"No"},{"value":"3. Does patient have Stage IIIB with malignant pleural effusion, Stage IV, or recurrent NSCLC? And may patient have had only 1 prior chemotherapy regimen for advanced NSCLC in Phase II?","valueDescription":"3. Does patient have Stage IIIB with malignant pleural effusion, Stage IV, or recurrent NSCLC? And may patient have had only 1 prior chemotherapy regimen for advanced NSCLC in Phase II?","ValueMeaning":{"publicId":"2580292","version":"1","preferredName":"3. Does patient have Stage IIIB with malignant pleural effusion, Stage IV, or recurrent NSCLC? And may patient have had only 1 prior chemotherapy regimen for advanced NSCLC in Phase II?","longName":"2580292","preferredDefinition":"3. Does patient have Stage IIIB with malignant pleural effusion, Stage IV, or recurrent NSCLC? And may patient have had only 1 prior chemotherapy regimen for advanced NSCLC in Phase II?","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-06B1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-20","modifiedBy":"REEVESD","dateModified":"2006-07-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"19089E42-E23B-2EAD-E044-0003BA3F9857","beginDate":"2006-07-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-20","modifiedBy":"REEVESD","dateModified":"2006-07-20","deletedIndicator":"No"},{"value":"4. Does patient have measurable disease defined by the RECIST criteria (unidimensionally measurable) by physical examination, X-ray, computed tomography (CT), or MRI scan in Phase II?","valueDescription":"4. Does patient have measurable disease defined by the RECIST criteria (unidimensionally measurable) by physical examination, X-ray, computed tomography (CT), or MRI scan in Phase II?","ValueMeaning":{"publicId":"2580293","version":"1","preferredName":"4. Does patient have measurable disease defined by the RECIST criteria (unidimensionally measurable) by physical examination, X-ray, computed tomography (CT), or MRI scan in Phase II?","longName":"2580293","preferredDefinition":"4. Does patient have measurable disease defined by the RECIST criteria (unidimensionally measurable) by physical examination, X-ray, computed tomography (CT), or MRI scan in Phase II?","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-06B2-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-20","modifiedBy":"REEVESD","dateModified":"2006-07-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"19089E42-E247-2EAD-E044-0003BA3F9857","beginDate":"2006-07-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-20","modifiedBy":"REEVESD","dateModified":"2006-07-20","deletedIndicator":"No"},{"value":"5. Is patient at least 18 years of age or older?","valueDescription":"5. Is patient at least 18 years of age or older?","ValueMeaning":{"publicId":"2580294","version":"1","preferredName":"5. Is patient at least 18 years of age or older?","longName":"2580294","preferredDefinition":"5. Is patient at least 18 years of age or older?","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-06B3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-20","modifiedBy":"REEVESD","dateModified":"2006-07-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"19089E42-E253-2EAD-E044-0003BA3F9857","beginDate":"2006-07-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-20","modifiedBy":"REEVESD","dateModified":"2006-07-20","deletedIndicator":"No"},{"value":"6. Does patient have anticipated survival of at least 8 weeks?","valueDescription":"6. Does patient have anticipated survival of at least 8 weeks?","ValueMeaning":{"publicId":"2580295","version":"1","preferredName":"6. Does patient have anticipated survival of at least 8 weeks?","longName":"2580295","preferredDefinition":"6. Does patient have anticipated survival of at least 8 weeks?","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-06B4-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-21","modifiedBy":"REEVESD","dateModified":"2006-07-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"191A9A33-1A4D-326B-E044-0003BA3F9857","beginDate":"2006-07-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-21","modifiedBy":"REEVESD","dateModified":"2006-07-21","deletedIndicator":"No"},{"value":"7. Does Patient have ECOG performance status of 0.1.2?","valueDescription":"7. Does Patient have ECOG performance status of 0.1.2?","ValueMeaning":{"publicId":"2580296","version":"1","preferredName":"7. Does Patient have ECOG performance status of 0.1.2?","longName":"2580296","preferredDefinition":"7. Does Patient have ECOG performance status of 0.1.2?","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-06B5-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-21","modifiedBy":"REEVESD","dateModified":"2006-07-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"191A9A33-1A59-326B-E044-0003BA3F9857","beginDate":"2006-07-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-21","modifiedBy":"REEVESD","dateModified":"2006-07-21","deletedIndicator":"No"},{"value":"8. Is patient fully informed about their illness and the investigational nature of the study protocol (including foreseeable risks and possible side effects), and sign an informed consent?","valueDescription":"8. Is patient fully informed about their illness and the investigational nature of the study protocol (including foreseeable risks and possible side effects), and sign an informed consent?","ValueMeaning":{"publicId":"2580297","version":"1","preferredName":"8. Is patient fully informed about their illness and the investigational nature of the study protocol (including foreseeable risks and possible side effects), and sign an informed consent?","longName":"2580297","preferredDefinition":"8. Is patient fully informed about their illness and the investigational nature of the study protocol (including foreseeable risks and possible side effects), and sign an informed consent?","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-06B6-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-21","modifiedBy":"REEVESD","dateModified":"2006-07-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"191A9A33-1A65-326B-E044-0003BA3F9857","beginDate":"2006-07-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-21","modifiedBy":"REEVESD","dateModified":"2006-07-21","deletedIndicator":"No"},{"value":"9. Does patient have Hematologic: ANC >= 1,500/mm3, WBC >= 2,000/mm3; hemoglobin >= 9.0g/dl, and platelet count >=100,000/mm3?","valueDescription":"9. Does patient have Hematologic: ANC >= 1,500/mm3, WBC >= 2,000/mm3; hemoglobin >= 9.0g/dl, and platelet count >=100,000/mm3?","ValueMeaning":{"publicId":"2580298","version":"1","preferredName":"9. Does patient have Hematologic: ANC >= 1,500/mm3, WBC >= 2,000/mm3; hemoglobin >= 9.0g/dl, and platelet count >=100,000/mm3?","longName":"2580298","preferredDefinition":"9. Does patient have Hematologic: ANC >= 1,500/mm3, WBC >= 2,000/mm3; hemoglobin >= 9.0g/dl, and platelet count >=100,000/mm3?","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-06B7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-21","modifiedBy":"REEVESD","dateModified":"2006-07-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"191A9A33-1A71-326B-E044-0003BA3F9857","beginDate":"2006-07-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-21","modifiedBy":"REEVESD","dateModified":"2006-07-21","deletedIndicator":"No"},{"value":"10. Is Hepatic: total bilirubin  within normal limits?","valueDescription":"10. Is Hepatic: total bilirubin  within normal limits?","ValueMeaning":{"publicId":"2580299","version":"1","preferredName":"10. Is Hepatic: total bilirubin  within normal limits?","longName":"2580299","preferredDefinition":"10. Is Hepatic: total bilirubin  within normal limits?","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-06B8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-21","modifiedBy":"REEVESD","dateModified":"2006-07-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"191A9A33-1A7D-326B-E044-0003BA3F9857","beginDate":"2006-07-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-21","modifiedBy":"REEVESD","dateModified":"2006-07-21","deletedIndicator":"No"},{"value":"11. May Hepatic: transaminases(SGOT and/or SGPT) be up to 2.5 x institutional ULN if alkaline phosphatase is <= ULN, or may alkaline phosphatase be up to 4 x ULN if transaminases are <= ULN?","valueDescription":"11. May Hepatic: transaminases(SGOT and/or SGPT) be up to 2.5 x institutional ULN if alkaline phosphatase is <= ULN, or may alkaline phosphatase be up to 4 x ULN if transaminases are <= ULN?","ValueMeaning":{"publicId":"2580361","version":"1","preferredName":"11. May Hepatic: transaminases(SGOT and/or SGPT) be up to 2.5 x institutional ULN if alkaline phosphatase is <= ULN, or may alkaline phosphatase be up to 4 x ULN if transaminases are <= ULN?","longName":"2580361","preferredDefinition":"11. May Hepatic: transaminases(SGOT and/or SGPT) be up to 2.5 x institutional ULN if alkaline phosphatase is <= ULN, or may alkaline phosphatase be up to 4 x ULN if transaminases are <= ULN?","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-06F6-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"REEVESD","dateModified":"2006-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"19E090A0-663A-42A6-E044-0003BA3F9857","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"REEVESD","dateModified":"2006-07-31","deletedIndicator":"No"},{"value":"12. Is Renal: Serum creatinine < 1.5 mg/dl or creatinine clearance < 60 ml/min?","valueDescription":"12. Is Renal: Serum creatinine < 1.5 mg/dl or creatinine clearance < 60 ml/min?","ValueMeaning":{"publicId":"2580362","version":"1","preferredName":"12. Is Renal: Serum creatinine < 1.5 mg/dl or creatinine clearance < 60 ml/min?","longName":"2580362","preferredDefinition":"12. Is Renal: Serum creatinine < 1.5 mg/dl or creatinine clearance < 60 ml/min?","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-06F7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"REEVESD","dateModified":"2006-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"19E090A0-6646-42A6-E044-0003BA3F9857","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"REEVESD","dateModified":"2006-07-31","deletedIndicator":"No"},{"value":"14. Does woman of childbearing age have a negative pregnancy test (serum b-HCG) with a sensitivity of at least 50 mlU/L within 7 days prior to the initiation of treatment?","valueDescription":"14. Does woman of childbearing age have a negative pregnancy test (serum b-HCG) with a sensitivity of at least 50 mlU/L within 7 days prior to the initiation of treatment?","ValueMeaning":{"publicId":"2580365","version":"1","preferredName":"14. Does woman of childbearing age have a negative pregnancy test (serum b-HCG) with a sensitivity of at least 50 mlU/L within 7 days prior to the initiation of treatment?","longName":"2580365","preferredDefinition":"14. Does woman of childbearing age have a negative pregnancy test (serum b-HCG) with a sensitivity of at least 50 mlU/L within 7 days prior to the initiation of treatment?","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-06FA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"REEVESD","dateModified":"2006-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"19E090A0-665E-42A6-E044-0003BA3F9857","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"REEVESD","dateModified":"2006-07-31","deletedIndicator":"No"},{"value":"15. Does woman have used effective contraception or been sexually abstinent for at least 4 weeks prior to the negative pregnancy test through entry into the study?","valueDescription":"15. Does woman have used effective contraception or been sexually abstinent for at least 4 weeks prior to the negative pregnancy test through entry into the study?","ValueMeaning":{"publicId":"2580368","version":"1","preferredName":"15. Does woman have used effective contraception or been sexually abstinent for at least 4 weeks prior to the negative pregnancy test through entry into the study?","longName":"2580368","preferredDefinition":"15. Does woman have used effective contraception or been sexually abstinent for at least 4 weeks prior to the negative pregnancy test through entry into the study?","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-06FD-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"REEVESD","dateModified":"2006-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"19E090A0-666A-42A6-E044-0003BA3F9857","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"REEVESD","dateModified":"2006-07-31","deletedIndicator":"No"},{"value":"16. Are lactating mothers prohibited from breast-feeding while on treatment?","valueDescription":"16. Are lactating mothers prohibited from breast-feeding while on treatment?","ValueMeaning":{"publicId":"2580369","version":"1","preferredName":"16. Are lactating mothers prohibited from breast-feeding while on treatment?","longName":"2580369","preferredDefinition":"16. Are lactating mothers prohibited from breast-feeding while on treatment?","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-06FE-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"REEVESD","dateModified":"2006-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"19E090A0-6676-42A6-E044-0003BA3F9857","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"REEVESD","dateModified":"2006-07-31","deletedIndicator":"No"},{"value":"17. Are men and women of childbearing potential willingly consent to use effective contraception while on treatment and for a reasonable period thereafter?","valueDescription":"17. Are men and women of childbearing potential willingly consent to use effective contraception while on treatment and for a reasonable period thereafter?","ValueMeaning":{"publicId":"2580370","version":"1","preferredName":"17. Are men and women of childbearing potential willingly consent to use effective contraception while on treatment and for a reasonable period thereafter?","longName":"2580370","preferredDefinition":"17. Are men and women of childbearing potential willingly consent to use effective contraception while on treatment and for a reasonable period thereafter?","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-06FF-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"REEVESD","dateModified":"2006-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"19E090A0-6682-42A6-E044-0003BA3F9857","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"REEVESD","dateModified":"2006-07-31","deletedIndicator":"No"},{"value":"18. Is there any evidence of active infection that requires antibiotic therapy?","valueDescription":"18. Is there any evidence of active infection that requires antibiotic therapy?","ValueMeaning":{"publicId":"2580371","version":"1","preferredName":"18. Is there any evidence of active infection that requires antibiotic therapy?","longName":"2580371","preferredDefinition":"18. Is there any evidence of active infection that requires antibiotic therapy?","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0700-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"REEVESD","dateModified":"2006-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"19E090A0-668E-42A6-E044-0003BA3F9857","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"REEVESD","dateModified":"2006-07-31","deletedIndicator":"No"},{"value":"19. Does patient have recovered from transient toxicities of previous anti-cancer therapies?","valueDescription":"19. Does patient have recovered from transient toxicities of previous anti-cancer therapies?","ValueMeaning":{"publicId":"2580372","version":"1","preferredName":"19. Does patient have recovered from transient toxicities of previous anti-cancer therapies?","longName":"2580372","preferredDefinition":"19. Does patient have recovered from transient toxicities of previous anti-cancer therapies?","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0701-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"REEVESD","dateModified":"2006-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"19E090A0-669A-42A6-E044-0003BA3F9857","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"REEVESD","dateModified":"2006-07-31","deletedIndicator":"No"},{"value":"20. If present, is peripheral neuropathy <=grade 1?","valueDescription":"20. If present, is peripheral neuropathy <=grade 1?","ValueMeaning":{"publicId":"2580373","version":"1","preferredName":"20. If present, is peripheral neuropathy <=grade 1?","longName":"2580373","preferredDefinition":"20. If present, is peripheral neuropathy <=grade 1?","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0702-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"REEVESD","dateModified":"2006-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"19E090A0-66A6-42A6-E044-0003BA3F9857","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"REEVESD","dateModified":"2006-07-31","deletedIndicator":"No"},{"value":"21. Do baseline laboratory values have been performed with 7 days of patient registration? And do tumor measurements for all involved sites have been performed within 4 weeks of patient registration?","valueDescription":"21. Do baseline laboratory values have been performed with 7 days of patient registration? And do tumor measurements for all involved sites have been performed within 4 weeks of patient registration?","ValueMeaning":{"publicId":"2580374","version":"1","preferredName":"21. Do baseline laboratory values have been performed with 7 days of patient registration? And do tumor measurements for all involved sites have been performed within 4 weeks of patient registration?","longName":"2580374","preferredDefinition":"21. Do baseline laboratory values have been performed with 7 days of patient registration? And do tumor measurements for all involved sites have been performed within 4 weeks of patient registration?","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0703-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"REEVESD","dateModified":"2006-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"19E090A0-66B2-42A6-E044-0003BA3F9857","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"REEVESD","dateModified":"2006-07-31","deletedIndicator":"No"},{"value":"13. Is fasting serum triglyceride within normal limits or \"normalized\" prior to study entry with appropriate intervention such as the use of an antilipid agent?","valueDescription":"13. Is fasting serum triglyceride within normal limits or normalized prior to study entry with appropriate intervention such as the use of an antilipid agent?","ValueMeaning":{"publicId":"2580364","version":"1","preferredName":"13. Is fasting serum triglyceride within normal limits or normalized prior to study entry with appropriate intervention such as the use of an antilipid agent?","longName":"2580364","preferredDefinition":"13. Is fasting serum triglyceride within normal limits or normalized prior to study entry with appropriate intervention such as the use of an antilipid agent?","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-06F9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"COOPERM","dateModified":"2020-03-05","changeDescription":"Removed special characters for MDR data migration. 3.5.20 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A1C6EA6B-BAA1-4CCF-E053-F662850A2272","beginDate":"2006-07-31","endDate":null,"createdBy":"TSESU","dateCreated":"2020-03-26","modifiedBy":"ONEDATA","dateModified":"2020-03-26","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2261898","version":"1","preferredName":"Text Name","preferredDefinition":"Text; the words of something written.:The words or language units by which a thing is known.","longName":"C25704:C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Text","conceptCode":"C25704","definition":"The words of something written.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FBDEE8CB-7C8A-5E8A-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-15","modifiedBy":"ONEDATA","dateModified":"2005-07-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"19089E82-8B67-2E38-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-20","modifiedBy":"TSESU","dateModified":"2020-03-26","changeDescription":"Updated PV to remove special characters for MDR data migration. 3.26.20 smt","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2812367","version":"1","longName":"caBIG","context":"CCR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Inclusion Criteria","type":"Preferred Question Text","description":"Inclusion Criteria","url":null,"context":"NCIP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"19E0B524-D9EC-469E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-31","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-07-31","modifiedBy":"REEVESD","dateModified":"2006-07-31","changeDescription":"Curated to support C3PR application.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}